|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes显示文摘This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further research in this understudied malignancy. Pancreatic adenocarcinoma is a lethal condition with a rising incidence, predicted to become the second leading cause of cancer death in some regions. It often presents at an advanced stage, which contributes to poor five-year survival rates of 2%-9%, ranking firmly last amongst all cancer sites in terms of prognostic outcomes for patients. Better understanding of the risk factors and symptoms associated with this disease is essential to inform both health professionals and the general population of potential preventive and/or early detection measures. The identification of high-risk patients who could benefit from screening to detect pre-malignant conditions such as pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms and mucinous cystic neoplasms is urgently required, however an acceptable screening test has yet to be identified. The management of pancreatic adenocarcinoma is evolving, with the introduction of new surgical techniques and medical therapies such as laparoscopic techniques and neo-adjuvant chemoradiotherapy, however this has only led to modest improvements in outcomes. The identification of novel biomarkers is desirable to move towards a precision medicine era, where pancreatic cancer therapy can be tailored to the individual patient, while unnecessary treatments that have negative consequences on quality of life could be prevented for others. Research efforts must also focus on the development of new agents and delivery systems. Overall, considerable progress is required to reduce the burden associated with pancreatic cancer. Recent, renewed efforts to fund large consortia and research into pancreatic adenocarcinoma are welcomed, but further streams will be necessary to facilitate the momentum needed to bring breakthroughs seen for other cancer sites. | Andrew McGuigan Paul Kelly Richard C Turkington Claire Jones Helen G Coleman R Stephen McCain | 2018 | World Journal of Gastroenterology2018，24，43： | 140 |
| 2 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis. | Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton | 2017 | World Journal of Gastroenterology2017，23，1： | 18 |
| 3 | Nat Genet:单基因突变导致过敏性皮炎的发生显示文摘最近,研究者们鉴定出了一类导致神经性皮炎发生的关键基因突变:CARDll。来自美国NIH过敏与传染病研究所的研究者们通过对四个没有血缘关系的患病家庭进行分析,发现了这一导致疾病产生的基因、 | Chi A Ma, Yuan Zhang, Michael A Weinreich, Jonathan J Lyons, Celeste G Nelson, Thomas DiMaggio, Kelly D Stone, Joshua D Milner Jeffrey R Stinson, Elisa Ruffo, Batsukh Dorjbal, Swadhinya Arjunaraja, Kelsey Voss, Andrew L Snow Jordan K Abbott, Pia J Hauk, Paul R Reynolds, Erwin W Gelfand Elisa Ruffo Salomé Glauzy, Natsuko Yamakawa, Eric Meffre Jennifer Stoddard, Julie Niemela, Sergio D Rosenzweig Yu Zhang, Helen F Matthews Joshua J McElwee Nina Jones Alejandro Palma, Matías Oleastro, Emma Prieto, Andrea R Bernasconi, Geronimo Dubra, Silvia Danielian, Jonathan Zaiat, Marcelo A Marti Brian Kim Megan A Cooper Neil Romberg | 2017 | 现代生物医学进展2017，17，27： | 3 |
| 4 | The Importance of Medial Support in Locked Plating of Proximal Humerus Fractures显示文摘 | Michael J Gardner Yoram Weil Joseph U Barker Bryan T Kelly David L Helfet Dean G Lorich | 2007 | Journal of Orthopaedic Trauma2007，，3： | 2 |
| 5 | An introduction to wavelet analysis in oceanography and meteorology: with application to the dispersion of Yannai waves显示文摘 | Meyers S D Kelly B G O'Brien J J | 1993 | Mon Wea Rev1993，121，10： | 2 |
| 6 | Nitrogen dynamics following field application of biochar in a temperate North American maize-based production system显示文摘 | David Güere?a Johannes Lehmann Kelly Hanley Akio Enders Charles Hyland Susan Riha | 2013 | Plant and Soil2013，，1： | 2 |
| 7 | Severe Hand, Foot, and Mouth Disease Associated with Coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 201 1 - February 2012显示文摘 | McIntyre Mary G Stevens Kelly M Davidson Sherri Pippin Tina Magill Dagny Kulhanjian Julie A Kelly Daniel Greenhow Tara L Salas Maria L Yagi Shigeo Padilla Tasha Berumen Ricardo Glaser Carol Landry Marie Louise Lott Jason Chen Lei Paulson | 2012 | EN2012，，12： | 2 |
| 8 | Aggressive surgery for metastatic liver neuroendocrine tumors显示文摘 | Jeffrey A Norton Robert S Warren Mary G Kelly Marlene B Zuraek Robert T Jensen | 2003 | Surgery2003，，： | 2 |
| 9 | Field trials of suction caissons in clay for offshore wind turbine foundations 显示文摘 | Houlsby G T Kelly R B Huxtable J | 2005 | Geoteehnique2005，25，4： | 1 |
| 10 | Pharmacokinetic studies on minocycline in man显示文摘 | MacDONAD H KELLY R G ALLEN E S | 1973 | Clin Pharmacol Ther1973，14，5： | 1 |
| 11 | Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1显示文摘 | FUKUDA R KELLY B SEMENZA G L | 2003 | Cancer Res2003，63，9： | 1 |
| 12 | CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines 显示文摘 | Wang Y F Kelly C G Jaana T | 2001 | Immunity2001，15，6： | 1 |
| 13 | Ultrafine gained ferrite formed by interrupted hottorsion of plain carton steel显示文摘 | Kelly G L Beladi H Hedgson P | 2002 | ISIJ International2002，42，12： | 1 |
| 14 | Genetics of myeloid leukemias显示文摘 | KELLY L M GILLILAND D G | 2002 | Annu Rev Genomics Hum Genet2002，3，： | 1 |
| 15 | Mechanical properties of nanocrystalline nickel produced by electrodeposition显示文摘 | Ebrahimi F Bourne G R Kelly M S | 1999 | Nanostructured Materials1999，11，3： | 1 |
| 16 | Use and impact of satellite atmospheric motion winds on ECMWF analyses and forecasts显示文摘 | Tomassini M Kelly G Saunders R | 1999 | Monthly Weather Review1999，127，6： | 1 |
| 17 | Hydroxylated and methoxylated polybrorninated diphenyl ethers in a Canadian Arctic marine food web 显示文摘 | KELLY B C IKONOMOU M G BLAIR J D | 2008 | Environmental Science & Technolo- gy2008，42，19： | 1 |
| 18 | Therapeutic Efficacy by Recombinant Human Granulocyte/Monocyte-Colony Stimulating Factor on Mucositis Occurring in Patients with Oral and Oropharynx Tumors Treated with Curative Radiotherapy显示文摘 | Masucci G Broman P Kelly C | | 0，，03： | 1 |
| 19 | Hub networks and simulated schedule delay显示文摘 | Grove P G O'Kelly M E | 1986 | Papers in Regional Science1986，59，1： | 1 |
| 20 | Adiponectin in re- lation to insulin sensitivity and insulin secretion in the develop- ment of type 2 diabetes: a prospective study in 64-year-old women显示文摘 | Fagerberg B Kellis D Bergstrom G | 2011 | J Intern Med2011，269，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员